CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 366 enrolled
Drug / intervention
PF-06651600 +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03715829
NCT03715829Phase 2Completed
CompareCT.gov

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO

Pfizer·interventional·Posted Oct 23, 2018·Updated Mar 25, 2022

In Brief

A Phase 2 clinical trial evaluating PF-06651600, placebo, and 2 other interventions for Active Non-segmental Vitiligo. Completed, enrolled 366 participants across 92 sites in 10 countries.

Detailed Summary

This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week Follow up Period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActive Non-segmental Vitiligo
CountriesAustralia, Belgium, Canada, Germany, Italy, Japan, South Korea, Spain, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 23, 2018
Enrollment StartNov 26, 2018
Primary CompletionFeb 5, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.7 years ago

Interventions

PF-06651600drug

Induction dose 1. Oral tablet taken QD

PF-06651600drug

Induction dose 2. Oral tablet taken QD

PF-06651600drug

Maintenance dose A. Oral tablet taken QD

PF-06651600drug

Maintenance Dose B. Oral tablet taken QD

PF-06651600drug

Maintenance Dose C. Oral tablet taken QD

placebodrug

placebo

PF06700841drug

Oral tablet taken QD

narrow-band UVB phototherapydevice

Phototherapy will be combined with PF-06651600